CHITA – a registry of in vitro NAMs
Has FDA lost it’s way with NAMs? NAMs or New Alternative Methodologies is the term used by FDA for new regulatory tools to improve predictivity and help replace, reduce and/or…
It takes courage to address common pitfalls in drug discovery and perseverance to traverse the route. In my work and as an advisor I’ve seen 100s of early-stage drug discovery…
If phenotypic screening is driving innovation in drug discovery, network biology is the fuel. In phenotypic screening, compounds are tested for their functional effects on cellular responses in a target agnostic…
The selection of chemical matter to be used for screening is a major discussion topic for phenotypic drug discovery (PDD) researchers. At the recent Keystone Symposium on PDD, several talks were…
